Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710526 · ClinicalTrials.gov registry record · Phase 2
Phase II Pharmacokinetics Study of CAM2038
A Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by Braeburn Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 3
- Study locations
NCT02710526: Completed Phase 2 study of Chronic Pain and Opioid Use Disorder, sponsored by Braeburn Pharmaceuticals.
NCT02710526 is a Phase 2 study of Chronic Pain and Opioid Use Disorder that has completed, run by Braeburn Pharmaceuticals. The registered enrollment target is 66 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710526, a Phase 2 study of Chronic Pain and Opioid Use Disorder, has completed, sponsored by Braeburn Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 3
- Study locations
Study Summary
Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
Primary Outcome
AUCss (area under the plasma concentration-time curve during a 7-day dosing interval at steady state) for each injection site, i.e., buttock (reference), abdomen, thigh and back of upper arm-Buprenorphine for the Evaluable Pharmacokinetic (PKEVAL) Population
Conditions Studied
Interventions
- DRUG CAM2038
Study Locations (3)
Alabama
- Parkway Medical - Birmingham
New Jersey
- Hassman Research Institute - Berlin
Oklahoma
- The Rivus Wellness & Research Institute - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-07-03 |
| Phase | Phase 2 |
What the finished NCT02710526 record still lists
NCT02710526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 1 intervention - of which CAM2038 is the first listed.
NCT02710526 reports a single indexed study location in Alabama, New Jersey, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT02710526 about?
NCT02710526 is a clinical study titled "Phase II Pharmacokinetics Study of CAM2038". Phase II, open label, partially randomized, three treatment group study designed to evaluate the steady state pharmacokinetics of buprenorphine and norbuprenorphine following repeated subcutaneous administrations of CAM2038.
What is the current status of trial NCT02710526?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-02. Estimated completion is 2017-07-03.
What conditions does trial NCT02710526 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.
What interventions are being tested in trial NCT02710526?
The interventions under investigation include: CAM2038 (DRUG).
Who is sponsoring clinical trial NCT02710526?
This trial is sponsored by Braeburn Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710526 being conducted?
This trial has 3 study locations across Alabama, New Jersey, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02710526's enrollment target sits among peer trials
66 170th of 301 higher than 131 of 301 other Chronic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
RECRUITING · Phase 2
-
The Role of Brain Dopamine in Chronic Pain
RECRUITING · Phase 2
-
Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
Dronabinol as an Adjunct for Reducing Pain
RECRUITING · Phase 2
-
Pilot Study: Impact of Biomarker-Guided Dietary Supplementation on Quality-of-Life Measures in Subjects With Chronic Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia